While anti-GD2 mAb alone produced some anti-tumor activity in neuroblastoma patients, combining the mAb with GM-CSF and interleukin 2 (IL2) to further activate immune effector cells enabled potent clinical anti-tumor efficacy of anti-GD2 mAb. This evidence concerns the gene IL2 and neoplasm.